Pharmaceutical Treatments for Typical CKD Comorbidities

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 834

Special Issue Editors


E-Mail Website
Guest Editor
1. UOSD Nephrology and Dialysis, University Hospital Tor Vergata, Rome, Italy
2. Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
Interests: nutrition in chronic kidney disease; hemodialysis; natural active compounds for prevention of chronic non-communicable diseases; body composition assessment; uremic sarcopenia; oxidative stress; microbiome in CKD; endothelial dysfunction in CKD
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Systems Medicine, University of Rome, Tor Vergata, Italy
Interests: nutritional treatment; natural bioactive compounds; gut dysbiosis; chronic non-communicable diseases; oral food supplements; functional foods

Special Issue Information

Dear Colleagues,

Chronic kidney disease (CKD) is characterized by numerous metabolic disorders and comorbidities that increase the risk of its progression toward end-stage renal disease (ESRD) and the mortality risk, worsening the patient's quality of life. These comorbidities include diabetes mellitus, arterial hypertension, protein energy wasting, mineral bone disorders, metabolic acidosis, hyperhomocysteinemia, uremic sarcopenia, uremic gastropathy, normochromic and normocytic anemia, electrolyte imbalance, dyslipidemia and gut dysbiosis. In this context, the identification and use of new pharmacological treatments are of particular relevance for the clinical management of CKD patients.

The purpose of our Special Issue is to take stock of the most innovative pharmacological and non-pharmacological therapies that employ a holistic approach to treating CKD patients.

Prof. Annalisa Noce
Dr. Manuela Di Lauro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • natural bioactive compounds
  • adjuvant treatment
  • protein energy wasting
  • mineral bone disorders
  • metabolic acidosis
  • hyperhomocysteinemia
  • uremic sarcopenia
  • PLADO diet
  • anemia in CKD

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

24 pages, 1527 KiB  
Review
Innovative Treatments to Counteract Endothelial Dysfunction in Chronic Kidney Disease Patients
by Giulia Marrone, Kevin Cornali, Manuela Di Lauro, Maria Josè Ceravolo, Luca Di Marco, Simone Manca di Villahermosa, Anna Paola Mitterhofer and Annalisa Noce
Biomedicines 2024, 12(5), 1085; https://doi.org/10.3390/biomedicines12051085 - 14 May 2024
Viewed by 664
Abstract
In chronic kidney disease (CKD) patients, several risk factors contribute to the development of endothelial dysfunction (ED), which can be described as an alteration in the cell structure or in the function of the endothelium. Among the well-known CKD-related risk factors capable of [...] Read more.
In chronic kidney disease (CKD) patients, several risk factors contribute to the development of endothelial dysfunction (ED), which can be described as an alteration in the cell structure or in the function of the endothelium. Among the well-known CKD-related risk factors capable of altering the production of endothelium-derived relaxing factors, we include asymmetric dimethylarginine increase, reduced dimethylarginine dimethylamine hydrolase enzyme activity, low-grade chronic systemic inflammation, hyperhomocysteinemia, oxidative stress, insulin resistance, alteration of calcium phosphorus metabolism, and early aging. In this review, we also examined the most important techniques useful for studying ED in humans, which are divided into indirect and direct methods. The direct study of coronary endothelial function is considered the gold standard technique to evaluate if ED is present. In addition to the discussion of the main pharmacological treatments useful to counteract ED in CKD patients (namely sodium–glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonist), we elucidate innovative non-pharmacological treatments that are successful in accompanying the pharmacological ones. Among them, the most important are the consumption of extra virgin olive oil with high intake of minor polar compounds, adherence to a plant-dominant, low-protein diet (LPD), an adaptive physical activity program and, finally, ketoanalogue administration in combination with the LPD or the very low-protein diet. Full article
(This article belongs to the Special Issue Pharmaceutical Treatments for Typical CKD Comorbidities)
Show Figures

Figure 1

Back to TopTop